Abstract
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].
MeSH terms
-
Acetamides
-
Acetates / chemistry
-
Acetates / pharmacology
-
Acetates / therapeutic use*
-
Animals
-
Arteriosclerosis / drug therapy
-
Arteriosclerosis / enzymology
-
Clinical Trials as Topic / methods
-
Clinical Trials as Topic / statistics & numerical data
-
Drug Industry / legislation & jurisprudence
-
Drug Industry / methods*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Hyperlipidemias / drug therapy
-
Hyperlipidemias / enzymology
-
Sulfonamides
-
Sulfonic Acids / chemistry
-
Sulfonic Acids / pharmacology
-
Sulfonic Acids / therapeutic use*
Substances
-
Acetamides
-
Acetates
-
Enzyme Inhibitors
-
Sulfonamides
-
Sulfonic Acids
-
avasimibe